MedLumics is a medical imaging diagnostics company, specializing in advanced optical coherence tomography (OCT) technology. It has declared the closing of a 3.5 M € /4.7 M USD Series A financing.
Directed in association with Ysios Capital Partners and la Caixa, via Caixa Capital Risc, the funds would be employed to conclude the progress of the company’s innovative imaging diagnostic platform and its technical and executive team recruitment.
OCT is the latest imaging model that captures the patient’s sub-surface images of a tissue at a relatively higher resolution than magnetic resonance imaging (MRI) or ultrasound. It is frequently being employed in ophthalmology, although used in other areas including dentistry, oncology and cardiology. MedLumics’ imaging diagnostics platform leverages these challenges by incorporating the entire electrical and optical OCT components in a compressed system based on a microchip, providing vibrant, synchronized high-resolution diagnostic images with a tissue penetration of 2mm , allowing physicians to carry out a non-invasive optical digital biopsy of tissues , protecting vulnerable structures with reduced time period. The technology aids in the progress of OCT in health care, reducing production and maintenance costs in contrast to first generation OCT systems.
MedLumics’ platform technology application will initially concentrate on intravascular imaging in cardiology and dental implantology and other medical specialties as well.